[The efficacy of the complex medication Phyto-Hypophyson L in female, hormone-related sterility. A randomized, placebo-controlled clinical double-blind study].
OBJECTIVE
In a prospective, randomized, placebo-controlled, double-blind study, the effects of Phyto Hypophyson L (Steierl-Pharma GmbH, Herrsching, Germany), an Agnus castus-containing homeopathic preparation, were investigated in 67 women with fertility disorders.


METHODS
37 women with oligomenorrhea and 30 women with amenorrhea received 50 drops of Phyto Hypophyson L or placebo 3 times a day over 3 months or 3 cycles. OUTCOME MEASURE AND RESULTS: The outcome measure being spontaneous menstruation, improved concentration of progesterone in the luteal phase, shortening of the cycle, earlier ovulation, and pregnancy was achieved in 38 out of 67 women. It was achieved more often from women with oligomenorrhea in the Phyto Hypophyson L group compared to the placebo group (82 versus 45%, p = 0.021). However, there was no significant effect when viewing the whole group. The baby take-home rate during the therapy and 6 months after the end of the therapy showed a ratio of 6 : 2 (18.7 : 6.4%). This result was not significant. Furthermore, in the oligomenorrhea verum group we observed a significant increase of progesterone during the luteal phase compared to the oligomenorrhea placebo group. Only very few undesirable drug effects were observed.


CONCLUSIONS
In women with sterility and oligomenorrhea, a treatment with Phyto Hypophyson L can be recommended over a period of 3-6 months.
Bergmann
J
J
Abteilung für Gynäkologische Endokrinologie und Fertilitätsstörungen, Universitäts-Frauenklinik, Heidelberg.
Luft
B
B
Boehmann
S
S
Runnebaum
B
B
Gerhard
I
I
D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy; D004311:Double-Blind Method; D005260:Female; D006705:Homeopathy; D006801:Humans; D007231:Infant, Newborn; D007247:Infertility, Female / Q000188:drug therapy*; D009839:Oligomenorrhea / Q000188:drug therapy; D008517:Phytotherapy; D010919:Placebos; D010946:Plants, Medicinal; D011247:Pregnancy; D011256:Pregnancy Outcome; D011446:Prospective Studies; D020950:Vitex / Q000627:therapeutic use*
D010919:Placebos